In today’s global life sciences marketplace, our clients work hard to develop and introduce new products and technologies. However, we understand that competitive, regulatory and litigation challenges can arise at any point; and our lawyers are ready to help your organization overcome these obstacles. From initial conception to commercial viability, from market success to expansion, we provide our clients with strategic and practical legal advice.
learn more

News more

  • Summer @ Foley Hoag LLPFoley Hoag Launches New Microsite for Law Students as 2009 On-campus Interviews Commence  [Read More]
  • Working Mother and Flex-Time Lawyers Recognize Foley Hoag  [Read More]
  • Global Bio-Chem Technology Group Company Limited, Foley Hoag LLP, and Adduci, Mastriani & Schaumberg LLP Prevail in International Trade Commission Patent Infringement Investigation  [Read More]
  • Foley Hoag Joins American Lawyer's Select Group of Top 50 A-List Firms  [Read More]
  • Foley Hoag Files Amicus Brief for Biotechnology Industry Organization  [Read More]

Publications more

  • Economic Crisis Team Datasheet [Read More]
  • Failure to Obtain Opinion of Counsel May Be Evidence of Intent to Induce Infringement [Read More]
  • Final 409A Deadline Looming: All Deferred Compensation Arrangements Must be in Full Compliance by December 31, 2008 [Read More]
  • EEC Perspectives - September 2008 [Read More]
  • Hatch-Waxman Safe Harbor Inapplicable to Research Tools [Read More]

Events more

October 16, 2008 Personalized Medicine Coalition [Read More] The Ohio State University Medical Center
Columbus, Ohio
October 19, 2008 ACC Annual Meeting '08 [Read More] Washington State Convention & Trade Center
Seattle, WA
October 20, 2008 Molecular Diagnostics [Read More] Manchester Grand Hyatt Hotel
San Diego, CA
November 6, 2008 TCN: Funding Expedition™ Mixer [Read More] Foley Hoag LLP (Boston Office)
Boston, MA
November 12, 2008 American Conference Institute’s 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements: Allocating Rights, Responsibilities & Rewards in Licensing, Strategic Alliances and Partnering Deals [Read More] Helmsley Park Lane Hotel
New York, NY

Client Successes more

  • Biomedical Advanced Research and Development Authority (BARDA)
    In a move that created enormous opportunities for early-stage life sciences companies, last year the U.S. Congress revitalized the federal government’s program supporting the development of medical countermeasures critical to protecting the nation against bioterrorism and pandemic threats. The resulting legislation created an agency within the Department of Health and Human Services (HHS), the Biomedical Advanced Research and Development Authority (BARDA). BARDA will inject more than $1 billion into research, development, and procurement of vaccines, antivirals and diagnostics. BARDA enhances coordination between government and emerging companies through support of advanced research and development, the vital phase that occurs in between basic research and commercialization. On behalf of the venture capital firm, Kleiner Perkins Caulfield & Byers, Foley Hoag worked with the HHS, Congressional members, and staff to craft legislation strengthening the nation’s response to pandemic outbreaks and bioterrorism. The key financing aspect of the legislation provides much-needed funding to allow early stage companies to traverse the “valley of death” before product commercialization. The legislation authorizes the Secretary of HHS to expedite contracts and grants, and the Director of BARDA to identify areas of unmet need, spurring further innovation and investment. BARDA institutionalizes the important partnership between the federal government and the life sciences industry, critical to safety, innovation and economic vitality. [Read More]
  • HyperBranch Medical Technology, Inc.
    For our client HyperBranch Medical Technology, Inc., a leader in the field of polymeric medical sealants, we assisted with the intellectual property portfolio strategy in connection with obtaining CE Mark designation for the company’s OcuSeal product. OcuSeal is a liquid ocular bandage used to stabilize ocular wounds following surgical or non-surgical trauma. CE Marking denotes that a product complies with all requirements of European health, safety, and environmental product legislation, and is an important step in bringing products to market overseas. HyperBranch began its research in 2004 with the objective to develop strong enough polymer sealants to ultimately replace sutures that would be easy to use, and would not interfere with natural healing. The Durham, North Carolina medical device company has also, been developing advanced surgical sealants for dura (brain), pleural (lung) and hernia mesh fixation. These products are all at various stages of clinical and pre-clinical development. Read more about HyperBranch Medical Technology here. [Read More]